The Role of the Immune System in Endometriosis

Completed

• Conditions: Endometriosis; 10038612

• Registration Number: NL-OMON50014
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- Patients between 18-56 years with confirmed endometriosis planned for
surgical excision of endometriosis
- Patients being able to read and understand the patient information form
- Signed informed consent

Exclusion Criteria

- History of an autoimmune disease, specifically hepatitis A virus (HAV),
hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency
virus (HIV), or any other systemic intercurrent disease or condition that might
affect the immunocompetence of the patient
- Treatment with systemic highly immunosuppressive therapy (e.g. transplant
recipients)
- Use of systemic continuous corticosteroid therapy (e.g. prednisone i.v. or
p.o. >7.5 mg/day)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study parameter will be the presence of CD4+ and CD8+ T-lymphocytes<br /><br>in the different tissue samples. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Furthermore, we will assess patient factors and characteristics of the<br /><br>endometriotic lesion on the T-cell infiltration. </p><br>